Back to Browse Journals » Current Biomarker Findings » Volume 3

Urinary biomarkers of diabetic nephropathy

Authors Mehta S, Cabrera VJ, Upputalla R, Jim B

Published Date November 2013 Volume 2013:3 Pages 67—78

DOI http://dx.doi.org/10.2147/CBF.S36985

Received 15 August 2013, Accepted 26 September 2013, Published 25 November 2013

Swati Mehta,1 Valerie Jorge Cabrera,2 Roshni Upputalla,2 Belinda Jim2

1Department of Medicine, James J Peters VA Medical Center, Bronx, NY, USA; 2Division of Nephrology, Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA

Abstract: The fervent search for an early biomarker for diabetic nephropathy is continuing because this entity has become the leading cause of end-stage renal disease in many countries. Novel biomarkers are being described in a high-speed manner. Using urine as a biological source is especially appealing given its ease of collection and its ability to serve as a direct conduit to the site of injury. We begin by briefly discussing the merits and pitfalls of our gold standard of microalbuminuria, and shift quickly to several promising nontraditional protein and messenger (m)RNA biomarkers. The quality of the evidence for using urinary podocyte as a marker will be described. Exploring entire sets of protein in humans in terms of proteomics has been a favorite approach in the last decade because the technology of protein separation and mass spectrometry allows for the unbiased search for new biomarkers. Isolating urinary microRNA may become yet another preferred method because these small, noncoding mRNA that regulate gene expression are particularly stable and apt for biomarker studies. Finally, the latest development is perhaps the study of exosomes, which are nanometer particles derived from the fusion of internal vesicles to the plasma membrane. These particles harbor protein, mRNA, and microRNA that may be isolated for further study. With the advent of newer technologic approaches, we hope that these newly discovered biomarkers will be rigorously tested in large, prospective, clinical trials so they can be implemented in clinical practice.

Keywords: diabetes, predictor, proteinuria, albuminuria, exosomes, proteomics, podocyte

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers

Nagelschmitz J, Blunck M, Kraetzschmar J, Ludwig M, Wensing G, Hohlfeld T

Clinical Pharmacology: Advances and Applications 2014, 6:51-59

Published Date: 19 March 2014

Population pharmacokinetics of olprinone in healthy male volunteers

Kunisawa T, Kasai H, Suda M, Yoshimura M, Sugawara A, Izumi Y, Iida T, Kurosawa A, Iwasaki H

Clinical Pharmacology: Advances and Applications 2014, 6:43-50

Published Date: 4 March 2014

Detemir as a once-daily basal insulin in type 2 diabetes

Nelson SE

Clinical Pharmacology: Advances and Applications 2011, 3:27-37

Published Date: 18 August 2011